Role of targeted therapy in non-small cell lung cancer: Hype or hope?

Expert Review of Anticancer Therapy

Volumn 3, Issue 4, 2003, Pages 443-455

  Langer, Corey J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Angiogenesis; COX 2 inhibitors; EGFR; Famesyl transferase inhibitors; Inhibitors; Non small cell lung cancer; Protein kinase C ; Targeted therapy; Tirapazamine

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALPHA INTERFERON; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ERLOTINIB; ETOPOSIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GEMCITABINE; IRINOTECAN; ISIS 3521; LONAFARNIB; MARIMASTAT; NAVELBINE; PACLITAXEL; PRINOMASTAT; REBIMASTAT; SEMAXANIB; SQUALAMINE; SULINDAC SULFONE; TANOMASTAT; TAXANE DERIVATIVE; TIRAPAZAMINE; TRASTUZUMAB; UNINDEXED DRUG;

ACNE; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTHRITIS; BLEEDING; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEADACHE; HEARING LOSS; HEMOPTYSIS; HUMAN; LETHARGY; LOW DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PUSTULE; RASH; REVIEW; SINGLE DRUG DOSE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TINNITUS; VEIN THROMBOSIS;

EID: 0042510817     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.4.443     Document Type: Review

References (93)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer Statistics, 2000. CA Cancer J. Clin. 50, 7-33 (2000).
2. American Cancer Society. Cancer Facts and Figures 2001. American Cancer Society, NY, USA (2001).
3. Johnson DH. Treatment strategies for metastatic non-small cell lung cancer. Clin. Lung Cancer 1, 34-41 (1999).
4. Roszkowski K, Pluzanska A, Krazakowski M et al. A multicenter, randomized, Phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27, 145-157 (2000).
5. Ranson M, Davidson N, Nicolson M et al. Randomized trial of paclitaxel plus Supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst. 92, 1074-1080 (2000).
6. Anderson H, Cottier B, Nicolson M et al. Phase III study of gemcitabine (Gemzar) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC). Lung Cancer 18, 9 (1997) (Abstract 24).
7. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst. 91, 66-72 (1999).
8. Sandler A, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 18, 122-130 (2000).
9. Kelly K, Crowley J, Bunn P, Livingston RB, Gandara DR. A randomized Phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): a Southwest Oncology Group (SWOG) trial. Proc. Am. Soc. Clin. Oncol. 18, 461a (1999) (Abstract 1777).
10. Schiller JH, Harrington D, Belani C et al for the Eastern Co-operative Oncology Group. A comparison of four chemotherapy regimens for advanced non-small cell lung cancer (NSCLC). N. Engl. J. Med. 10(346), 92-98 (2000).
11. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20, 308a (2001) (Abstract 1227).
12. Van Meerbeeck JP, Smit EF, Lianes P et al. An EORTC randomized Phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20, 308a (2001) (Abstract 1228).
13. Belani C, Barstis J, Perry M et al. Phase II multicenter randomized trial of weekly paclitaxel (P) administered in combination with carboplatin (C) followed by maintenance P versus observation for patients (pts) with advanced and metastatic non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20, 323a (2001) (Abstract 1287).
14. Rodriguez J, Pawel J, Pluzanska A et al. A multicenter, randomized Phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) versus vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20, 314a (2001) (Abstract 1252).
15. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer 8, 3-9 (2001).
16. Fontanini G, Vignati S, Bigini D et al. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metabolic involvement of the hilar and mediastinal lymph node squamous subtypes. Eur. J. Cancer 31A, 178-183 (1995).
17. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 19(56), 6550-6565 (2000).
18. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res. 3, 2703-2707 (1997).
19. Fan Z, Baselga J, Masui H, Mendelson J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 53, 4637-4642 (1993).
20. Prewett M, Rockwell P, Rose C, Goldstein NI. Antitumor and cell cycle responses in KB cells treated with a chimeric antiEGFR monoclonal antibody in combination with cisplatin. Int. J. Oncol. 9, 217-224 (1996).
21. Perrotte P, Matsumoto T, Inoue K et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5, 257-265 (1999).
22. Milas L, Mason K, Hunter N et al. In vivo enhancement of tumor radio-response by C225 anti-epidermal growth factor receptor antibody. Clin. Cancer Res. 6, 701-708 (2000).
23. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18, 904-914 (2000).
24. Hong WK, Arquette M, Nabell L, Needle MN, Waksal HW, Herbst RS. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc. Am. Soc. Clin. Oncol. 20, 224a (2001) (Abstract 895).
25. Harari PM, Huang SM. Modulation of molecular targets to enhance radiation. Clin. Cancer Res. 6, 323-325 (2000).
26. Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Exp. Opin. Biol. Ther. 1, 1-14 (2001).
27. Kelly K, Hanna N, Rosenburg A, Bunn PA, Needle MN. A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with Stage IV non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (Abstract 2592) (2003).
28. Robert F, Blumenschein G, Dicke K, Tseng J, Saleh MN, Needle M. Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Am. Soc. Clin. Oncol. (2003) (Abstract 2587).
29. Kim E, Mauer A, Fossella FA. Phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 21, 293a (2002) (Abstract 1168).
30. Kumar R, Mandal M, Vadlamudi R. New insights into antiHER-2 receptor monoclonal antibody research. Semin. Oncol. 27(6 Suppl. 11), 89-91 (2000).
31. Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin. Oncol. 27(6 Suppl. 11), 21-25 (2000).
32. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2000).
33. Langer CJ, Adak S, Thor A, Vangel M, Johnson D. Phase II Eastern Co-operative Oncology Group (ECOG) pilot study of paclitaxel (P), carboplatin (C) and trastuzumab (T) in HER-2/neu (+) advanced non-small cell lung cancer (NSCLC): early analysis of E2598. Proc. Am. Soc. Clin. Oncol. 20, 315a (2001) (Abstract 1257).
34. Krug LM, Miller VA, Crapanzano J et al. Randomized Phase II trial of trastuzumab plus either weekly docetaxel or paclitaxel in previously untreated advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20, 333a (2001) (Abstract 1328).
35. Zinner RG, Glisson BS, Pisters KM et al. Cisplatin and gemcitabine combined with herceptin in patients (pts) with HER2 overexpressing, untreated, advanced, non-small cell lung cancer (NSCLC): a Phase II trial. Proc. Am. Soc. Clin. Oncol. 20, 328a (2001) (Abstract 1307).
36. Gatzemeier U, Groth G, Hirsh V et al. A randomized Phase II study of gemcitabine/cisplatin alone and with herceptin in patients with Her-2 positive non-small cell lung cancer. Eur. J. Cancer. 37, 50 (2001) (Abstract 173).
37. Hirsch F, Veve R, Varella-Garcia M, Bunn PA, Franklin WA. Evaluation of Her-2/neu expression in lung tumors by immunohistochemistry and fluorescence in situ hybridization (FISH). Proc. Am. Soc. Clin. Oncol. 19, 486a (2000) (Abstract 1900).
38. Verma S, Butts CA, Au HJ et al. Incidence of Her-2/neu in advanced non-small cell lung cancer and response to platinum-based chemotherapy. Proc. Am. Soc. Clin. Oncol. 20, 347a (2001) (Abstract 1384).
39. Baselga J, Averbuch SD. ZD 1839 (IRESSA) as an anticancer agent. Drugs 60, 33-40 (2000).
40. Barker AJ, Gibson KH, Grundy W et al. Studies leading to the identification of ZD1839 (IRESSA): an orally-active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 11, 1911-1914 (2001).
41. Meric JB, Faivre S, Monnerat C et al. ZD1839 'IRESSA,' Bull. Cancer 87, 873-876(2000).
42. Baselga J, Herbst R, LoRusso P et al. Continuous administration of AD1839 (IRESSA), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with five selected tumor types: evidence of activity and good tolerability. Proc. Am. Soc. Clin. Oncol. 19, 177a (2000) (Abstract 686).
43. Nagakawa K, Yamamoto N, Kudoh S et al. A phase intermittent dose-escalation trial of ZD 1839 (Iressa) in Japanese patients with solid malignant tumors. Proc. Am. Soc. Clin. Oncol. 19, 183a (2000) (Abstract 711).
44. Herbst RS, Khuri FR, Fossella FV et al. ZD 1839 (IRESSA™) in non-small cell lung cancer. Clin. Lung Cancer 3(1), 21-32 (2001).
45. Giaccone G, Johnson DH, Manegold C et al. A Phase III clinical trial of ZD 1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT- 1). Ann. Oncol. 13 (Suppl. 5), 2 (2002).
46. Johnson DH, Herbst R, Giaccone G et al. ZD 1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): initial results from a Phase III trial (INTACT-2). Ann. Oncol. 13(Suppl. 5), 127 (2002).
47. Kris MG, Herbst R, Rischin D et al. Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 IRESSA: a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer 29(Suppl. 1), 71 (2000) (Abstract 230).
48. Natale RB, Skarin A, Maddox A-M et al. Improvement in symptoms and quality of life for advanced non-small cell lung cancer patients receiving ZD 1839 (Iressa) in IDEAL 2. Proc. Am. Soc. Clin. Oncol. 21 (2002) (Abstract 1167).
49. Fukuoka M, Yano S, Giaccone G et al. Final results from a Phase II trial of ZD 1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL 1). Proc. Am. Soc. Clin. Oncol. 21 (2002) (Abstract 1188).
50. Perez-Soler R, Chachoua A, Huberman M et al. A Phase II trial of the epidermal growth factor receptor (EGFr) tyrosine kinase inhibitor OSI-774 following platinum-based chemotherapy in patients with advanced EGFr-expressing non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20, 310a (2000) (Abstract 1235).
51. Rowinsky E, Preston G, Ferrant KJ, Allen LF, Nadler PL, Bonomi P. A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20, 310a (2001) (Abstract 1235).
52. Pluda JM. Tumor-associated angiogenesis: mechanisms, clinical implications and therapeutic strategies. Semin. Oncol. 24, 203-218 (1997).
53. Herbst RS, Fidler IJ. Angiogenesis and lung cancer: potential for therapy. Clin. Cancer Res. 6, 4604-4606 (2000).
54. DeVore RF, Fehrenbacher L, Herbst RS et al. A randomized Phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with Stage IIIB/IV NSCLC. Proc. Am. Soc. Clin. Oncol 19, 485a (2000) (Abstract 1896).
55. Johnson DH, DeVore R, Kabbiinavar F, Herbst R, Holmgren E, Novotny W. Carboplatin (C) + paclitaxel (T) + rhuMAb-VEGF (AVF) may prolong survival in advance non-squamous lung cancer. Proc. Am. Soc. Clin. Oncol. 20, 315a (2001) (Abstract 1256).
56. Herbst RS, Tran HT, Mullani NA et al. Phase I clinical trial of recombinant human endostatin (rHE) in patients (Pts) with solid tumors: pharmacokinetic (PK), safety and efficacy analysis using surrogate end points of tissue and radiologic response. Proc. Am. Soc. Clin. Oncol. 20, 3a (2001) (Abstract 9).
57. Eder JP, Clark JW, Supko JG et al. A Phase I pharmacokinetic and pharmacodynamic trial of recombinant human endostatin. Proc. Am. Soc. Clin. Oncol. 20, 70a (2001) (Abstract 275).
58. Thomas JP, Sciller J, Lee F et al. A Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin. Proc. Am. Soc. Clin. Oncol. 20, 70a (2001) (Abstract 276).
59. DeMoraes ED, Fogler WE, Grant D et al. Recombinant human angiostatin (rhA): a Phase I clinical trial assessing safety, pharmacokinetics (PK) and pharmacodynamics (PD). Proc. Am. Soc. Clin. Oncol. 20, 3a (2001) (Abstract 10).
60. Puduvalli VK, Blumenschein GR, Hinton L et al. Phase I study of the angiogenesis inhibitor TNP-470 (T) in combination with paclitaxel (P) in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 19, 182a (2000) (Abstract 707).
61. Rosen PJ, Kabbinavar F, Figlin RA et al. A Phase I/II trial and pharmacokinetic (PK) study of SU 5416 in combination with paclitaxel and carboplatin. Proc. Am. Soc. Clin. Oncol. 20, 98a (2001) (Abstract 389).
62. Kuenan BC, Rosen L, Smit E et al. Dose-finding and pharmacokinetic study of cisplatin and gemcitabine and SU 5416 in patients with solid tumors. J. Clin. Oncol. 20, 1657-1667 (2001).
63. Michael M, Babic B, Tsao M et al. Prognostic significance of metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in patients with small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. 17, 563a (1998) (Abstract 2161).
64. Shepherd F, Giaccone G, Debruyne C et al. Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: an NIC-CTG and EDRTC study. Proc. Am. Soc. Clin. Oncol. 20, 4a (2001) (Abstract 11).
65. Smylie M, Mercier R, Aboulafia D et al. Phase III study of the matrix metalloproteinase (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20, 307a (2001) (Abstract 1226),
66. Bissett D, O'Byrne KJ, von Pawel J et al. Phase III study of the matrix metalloproteinase (MMP) inhibitor prinomastat in combination with gemcitabine and cisplatin in non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 21, 296a (2002) (Abstract 1183).
67. Gupta E, Huang M, Mao Y et al. Pharmacokinetic (PK) evaluation of BMS-275291, a matrix metalloproteinase (MMP) inhibitor, in cancer patients. Proc. Am. Soc. Clin. Oncol. 20, 76a (2001) (Abstract 301).
68. Huang M, Stolina M, Sharma S et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: upregulation of IL-10 and downregulation of IL-12 production. Cancer Res. 58, 1208-1216 (1998).
69. Sharma S, Stolina M, Lin Y et al. T-cell-derived IL-10 promotes lung cancer growth by suppressing both T-cell and APC function. J. Immunol. 163, 5020-5028 (1999).
70. Stolina M, Sharma S, Lin Y et al. Specific inhibition of cyclooxygenase-2 restores antitumor immunity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164, 361-370 (2000).
71. Dohadwala M, Luo J, Zhu L et al. Non-small cell lung cancer cycloxygenase-2-dependent invasion is mediated by CD44. J. Biol. Chem. 276, 20809-20812 (2001).
72. Soslow RA, Dannenberg AJ, Rush D et al. COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer 89, 2637 (2000).
73. Yoshimatsu K, Altorki NK, Golijanin D et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin. Cancer Res. 7, 2669 (2001).
74. Achiwa H, Yatabe Y, Hida T et al. Prognostic significance of elevated cyclooxygenase-2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res. 5, 1001 (1995).
75. Khuri FR, Wu H, Lee JJ et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in Stage I non-small cell lung cancer. Clin. Cancer Res. 7, 861 (2000).
76. Masferrer JL, Leahy KM, Koki AT et al. Anti-angiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60, 1306 (2000).
77. Hida T, Leyton J, Makheja AN et al. Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal anti-inflammatory drugs. Anticancer Res. 18, 775 (1998).
78. Altorki NK, Keresztes RS, Port JL et al. Celecoxib (Celebrex), a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer Proc. Am. Soc. Clin. Oncol. 21, 26a (2002) (Abstract 101).
79. Chan D, Soriano A, Helfrich B et al. Synergistic effects of exisulind with conventional chemopreventive and therapeutic agents against human lung cancer cells in vitro and in vivo. Proc. Am. Soc. Clin. Oncol. (1999) (Abstract 1884).
80. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyl transferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol. 17, 3631-3652 (1999).
81. Khuri FR, Glisson BS, Meyers ML et al. Phase I study of farnesyl transferase inhibitors (FTI) SCH66336 with paclitaxel in solid tumors: dose-finding, pharmacokinetic, efficacy/safety. Proc. Am. Soc. Clin. Oncol. 19, 205a (2000) (Abstract 799).
82. Patnaik A, Eckhardt SG, Izbicka E et al. A Phase I and pharmacokinetic (PK) study of the farnesyl transferase inhibitor, R115777 in combination with gemcitabine (gem). Proc. Am. Soc. Clin. Oncol. 19, 2a (2000) (Abstract 5A).
83. Goekjian PG, Jirousek MR. Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors and agents in development. Curr. Med. Chem. 6, 877-903 (1999).
84. Dean N, McKay R, Miraglia L et al. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-α expression. Cancer Res. 56, 3499-3507 (1996).
85. Geiger T, Muller M, Dean NM, Fabbro D. Antitumor activity of a PKC-α antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des. 13, 35-45 (1998).
86. Yuen AR, Halsey J, Fisher GA et al. Phase I study of an antisense oligonucleotide to protein kinase C-α (ISIS 3521/CGP 64128A) in patients with cancer. Clin. Cancer Res. 5, 3357-3363 (1999).
87. Lynch TJ, Raju R, Lind M et al. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: initial report. Am. Soc. Clin. Oncol. (2003) (Abstract 2504).
88. Von Pawel J, von Roemeling R, Gatzemeier U et al. Tirapazamine plus cisplatin versus cisplatin in advanced NSCLC: a report of the international Phase III CATAPULT I Study Group Trial. Proc. Am. Soc. Clin. Oncol. 17 (1998) (Abstract 1779).
89. Shepherd F, Koschel G, von Pawel J, Gatzemeier U, Van Zandwiyk N, Woll R. Comparison of tirapazamine and cisplatin versus etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC): final results of the international Phase III CATAPULT trial. Int. Assoc. Study Lung Cancer 28 (2000) (Abstract 87).
90. Williamson SK, Crowley JJ, Lara PN et al. Paclitaxel/carboplatin (PC) versus PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III Southwest Oncology Group (SWOG) trial. Am. Soc. Clin. Oncol. (2003) (Abstract 2502).
91. Korrapati V, Gaffney M, Larsson LG et al. Effect of HER-2/neu expression on survival in early stage non-small cell lung cancer (NSCLC). Am. Soc. Clin. Oncol. (1999) (Meeting abstract).
92. Laptalo L, Lara PN Jr, Lau DHM et al.. HER2/neu screening in advanced non-small cell lung cancer (NSCLC): a California Cancer Consortium trial of trastuzumab and docetaxel. Am. Soc. Clin. Oncol. (2001) (Abstract 1338).
93. Hirsch FR, Bunn PA, Miller YE et al. Intermediate biomarker profile for lung cancer chemoprevention trials. Am. Soc. Clin. Oncol. (2001) (Abstract 1286).